THE TRUTH ABOUT: 3 - Caught on Camera

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022

Upgrades

Benzinga · Jul 13, 2022

Peering Into Ecolab's Recent Short Interest

Ecolab's (NYSE:ECL) short percent of float has fallen 3.57% since its last report. The company recently reported that it has 2.01 million shares sold short, which is 0.81% of all regular shares that are available for trading.

Benzinga · Jun 30, 2022

Expert Ratings for Ecolab

Analysts have provided the following ratings for Ecolab (NYSE:ECL) within the last quarter:

Benzinga · Jun 27, 2022

If You Invested $100 In Ecolab 20 Years Ago, Here's How Much You Would Have Today

Ecolab (NYSE:ECL) has outperformed the market over the past 20 years by 3.15% on an annualized basis producing an average annual return of 10.32%. Currently, Ecolab has a market capitalization of $46.85 billion.

Benzinga · May 31, 2022

Where Ecolab Stands With Analysts

Within the last quarter, Ecolab (NYSE:ECL) has observed the following analyst ratings:

Benzinga · May 20, 2022

Here's How Much $1000 Invested In Ecolab 20 Years Ago Would Be Worth Today

Ecolab (NYSE:ECL) has outperformed the market over the past 20 years by 3.54% on an annualized basis producing an average annual return of 10.66%. Currently, Ecolab has a market capitalization of $48.78 billion.

Benzinga · Apr 27, 2022

JP Morgan Upgrades Ecolab: Here's What You Need To Know

JP Morgan upgraded its rating of Ecolab (NYSE:ECL) to Overweight with a price target of $190.00, changing its price target from $191.00 to $190.00. Shares of Ecolab are trading up 1.77% over the last 24 hours, at $171.46 per share.

Benzinga · Apr 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022

 

Benzinga · Apr 27, 2022

Analyst Ratings for Ecolab

Ecolab (NYSE:ECL) has observed the following analyst ratings within the last quarter:

Benzinga · Apr 27, 2022

Ecolab Q1 Bottom-Line Matches Street View; Clocks 13% Sales Growth

Ecolab Inc (NYSE:ECL) reported first-quarter FY22 sales growth of 13% year-on-year to $3.27 billion, beating the consensus of $3.20 billion. Sales from Global Industrial rose 12%, Global Institutional & Specialty climbed 19%, Global Healthcare & Life Sciences grew 29% Y/Y in fixed currency. Adjusted EPS of $0.82 was in-line with the analyst consensus. Selling,…

Benzinga · Apr 26, 2022